X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (725) 725
Publication (82) 82
Book Review (27) 27
Book Chapter (16) 16
Book / eBook (4) 4
Conference Proceeding (4) 4
Dissertation (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (515) 515
female (436) 436
index medicus (355) 355
animals (269) 269
tamoxifen (264) 264
selective estrogen receptor modulators - therapeutic use (237) 237
breast cancer (221) 221
oncology (199) 199
postmenopausal women (185) 185
estrogen (181) 181
breast neoplasms - drug therapy (172) 172
selective estrogen receptor modulators - pharmacology (147) 147
pharmacology & pharmacy (142) 142
cancer (128) 128
tamoxifen - therapeutic use (120) 120
raloxifene (115) 115
male (106) 106
selective estrogen receptor modulators (104) 104
middle aged (93) 93
selective estrogen receptor modulators - adverse effects (84) 84
tamoxifen - pharmacology (84) 84
rats (83) 83
prevention (81) 81
breast neoplasms - prevention & control (80) 80
medicine & public health (79) 79
aged (78) 78
antineoplastic agents, hormonal - therapeutic use (77) 77
research (77) 77
breast-cancer (75) 75
health aspects (74) 74
care and treatment (72) 72
breast neoplasms - pathology (70) 70
dose-response relationship, drug (69) 69
endocrinology & metabolism (69) 69
mice (69) 69
osteoporosis (69) 69
adult (68) 68
randomized-trial (68) 68
aromatase inhibitors (66) 66
selective estrogen receptor modulators - administration & dosage (66) 66
article (65) 65
drug therapy (65) 65
toxicology (65) 65
receptors, estrogen - metabolism (64) 64
analysis (62) 62
selective estrogen receptor modulator (62) 62
aromatase inhibitors - therapeutic use (61) 61
hormone replacement therapy (61) 61
bone-mineral density (59) 59
breast neoplasms - metabolism (59) 59
risk factors (59) 59
treatment outcome (59) 59
surgical adjuvant breast (56) 56
raloxifene hydrochloride - therapeutic use (55) 55
therapy (53) 53
endocrine therapy (51) 51
neurosciences (51) 51
chemotherapy (50) 50
postmenopause (50) 50
tamoxifen - adverse effects (50) 50
women (50) 50
clinical trials as topic (49) 49
double-blind (49) 49
estrogens (49) 49
estradiol (47) 47
selective estrogen receptor modulators - toxicity (46) 46
raloxifene hydrochloride - pharmacology (45) 45
biochemistry & molecular biology (43) 43
chemotherapy, adjuvant (42) 42
estrogen receptors (42) 42
estrogen-receptor (42) 42
rats, sprague-dawley (42) 42
apoptosis (41) 41
obstetrics & gynecology (41) 41
risk (41) 41
expression (40) 40
tamoxifen - administration & dosage (40) 40
chemoprevention (39) 39
internal medicine (39) 39
cell line, tumor (38) 38
chemistry, medicinal (38) 38
serm (38) 38
menopause (37) 37
phenols (37) 37
review (37) 37
anastrozole (36) 36
antineoplastic agents - therapeutic use (36) 36
antineoplastic agents, hormonal - adverse effects (36) 36
estrogen receptor (36) 36
randomized controlled trials as topic (36) 36
physiological aspects (34) 34
proteins (34) 34
clinical trials (33) 33
estradiol - pharmacology (33) 33
risk assessment (33) 33
selective estrogen receptor modulators - chemistry (33) 33
toxicity (32) 32
first-line therapy (31) 31
gene expression (31) 31
ligands (31) 31
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Biological Chemistry, ISSN 0021-9258, 2019, Volume 294, Issue 24, pp. 9461 - 9475
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2018, Volume 24, Issue 15, pp. 3510 - 3518
Purpose: AZD9496 is an oral nonsteroidal, small-molecule inhibitor of estrogen receptor alpha (ER alpha) and a potent and selective antagonist and degrader of... 
ENDOCRINE RESISTANCE | TRIALS | FULVESTRANT 500 MG | THERAPY | ONCOLOGY | TAMOXIFEN | ESR1 MUTATIONS | MECHANISMS | POSTMENOPAUSAL WOMEN | INHIBITOR | Nausea - chemically induced | Receptor, ErbB-2 - genetics | Cinnamates - administration & dosage | Humans | Middle Aged | Selective Estrogen Receptor Modulators - adverse effects | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Drug-Related Side Effects and Adverse Reactions - pathology | Dose-Response Relationship, Drug | Aged, 80 and over | Adult | Female | Selective Estrogen Receptor Modulators - administration & dosage | Breast Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Breast Neoplasms - genetics | Estrogen Receptor alpha - genetics | Indoles - adverse effects | Breast Neoplasms - pathology | Breast Neoplasms - blood | Cinnamates - adverse effects | Aged | Biomarkers, Tumor - genetics | Nausea - pathology | Drug-Related Side Effects and Adverse Reactions - classification | Tumor markers | Toxicity | Liver | Estrogens | Estrogen receptors | Diarrhea | Fatigue | Mass spectroscopy | Nausea | Breast cancer | Pharmacology | Patients | ErbB-2 protein | Anticancer properties | Safety engineering | Breast | Antitumor activity | Safety | Solid tumors | Mass spectrometry | Cancer | Tumors
Journal Article
Journal of Pharmacy and Pharmacology, ISSN 0022-3573, 07/2018, Volume 70, Issue 7, pp. 910 - 918
Journal Article
Drug Development Research, ISSN 0272-4391, 09/2018, Volume 79, Issue 6, pp. 275 - 286
Journal Article
Journal Article
Journal of Neuroinflammation, ISSN 1742-2094, 10/2017, Volume 14, Issue 1, pp. 197 - 8
Background: Estrogen deficiency is thought to be responsible for the higher frequency of aneurysmal subarachnoid hemorrhage in post-than premenopausal women.... 
Estrogen receptor | Selective estrogen receptor modulator | Subarachnoid hemorrhage | Intracranial aneurysm | Estrogen | RISK-FACTORS | RANDOMIZED CONTROLLED-TRIAL | IMMUNOLOGY | NEUROSCIENCES | HORMONAL FACTORS | FEMALE RATS | SMOOTH-MUSCLE-CELLS | MATRIX-METALLOPROTEINASE-9 EXPRESSION | POSTMENOPAUSAL WOMEN | NF-KAPPA-B | RNA, Messenger - metabolism | Tissue Inhibitor of Metalloproteinase-2 - genetics | Cerebral Arteries - drug effects | Dose-Response Relationship, Drug | Estrogen Receptor beta - metabolism | Tissue Inhibitor of Metalloproteinase-2 - metabolism | Estrogen Receptor beta - genetics | Selective Estrogen Receptor Modulators - therapeutic use | Hypertension - chemically induced | Estrogen Receptor alpha - metabolism | Female | Blood Pressure - drug effects | Intracranial Aneurysm - drug therapy | Cytokines - genetics | Disease Models, Animal | Ovariectomy | Gene Expression Regulation - genetics | Matrix Metalloproteinase 2 - metabolism | Rats | Rats, Sprague-Dawley | Gene Expression Regulation - drug effects | Intracranial Aneurysm - etiology | Animals | Estrogen Receptor alpha - genetics | Cerebral Arteries - metabolism | Hypertension - complications | Indoles - therapeutic use | Salts - toxicity | Hypertension | Stroke (Disease) | Intracranial aneurysms | Interleukins | Hormone therapy | RNA | Menopause | Phenols | Comparative analysis | Aneurysm | Rupture | Aneurysms | Estrogen receptors | mRNA | Matrix metalloproteinase | Kinases | Side effects | Xenoestrogens | Rodents | Hormone replacement therapy | Metalloproteinase | Blood pressure | Veins & arteries
Journal Article